Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

FormerXBC Inc XEBEQ

Xebec Adsorption Inc designs, engineers, and manufactures products that are used for purification, separation, dehydration, and filtration equipment for gases and compressed air. The company operates in three reportable segments: Systems, Corporate and other, and Support. Its product lines are natural gas dryers for natural gas refueling stations, compressed gas filtration, biogas purification, associated gas, engineering services, and air dryers. The company's geographical segments are United States, Canada, China, Other, Korea, Italy, and France.


GREY:XEBEQ - Post by User

Comment by tamaracktopon Nov 10, 2021 10:42am
148 Views
Post# 34109746

RE:RE:Tough Q3? .... probably

RE:RE:Tough Q3? .... probably
tamaracktop wrote:
ZouZS3 wrote:
Canaccord Genuity analyst Yuri Lynk has reaffirmed his "buy" recommendation for Xebec Adsorption. The Globe's David Leeder writes in the Eye On Equities column that Mr. Lynk trimmed his share target by 50 cents to $4.50. Analysts on average target the shares at $4.54. Mr. Lynk says in a note: "In hindsight, our upgrade of Xebec on July 6, 2021, was premature. ... We expect another tough quarter in Q3/2021 as inflationary pressures and logistical issues could pressure margins on the legacy contracts. However, as we move into 2022, these contracts should be well into the start-up and commissioning phase and, therefore, less of a drag. At the same time, the company is beginning production of 30 BGX-Biostream RNG upgrading units, which are standardized modular units that are built in a plant and shipped in a container. This should improve execution (and margin) in 2022.


That highlighted statement is debatable.
Very debatable.

Have you noticed that virtually every analyst covering all the companies in this space has cited inflation and supply chain disruptions a concern?

Legacy contracts are a wildcard.
Is it not possible that the diminishing negative influence of legacy contracts more than offset inflation's cost on the bottom line?

You bet it is.
Look what they did to the 4th quarter numbers versus the most recent quarter.

And those costs are going lower and lower to disappear in the near future.

<< Previous
Bullboard Posts
Next >>